Abstract:Background and purpose:Radiotherapy is used commonly to provide pain relief for bone metastases of breast cancer.Our aim was to evaluate the treatment outcome of palliative radiotherapy and the prognostic factors for survival in patients with bone metastasis of breast cancer. Methods :One hundred and eighty-six patients with bone metastases of breast cancer were treated with palliative radiotherapy between Jan.2000 and Aug.2005 were retrospectively analyzed.323 sites received irradiation.Radiation therapy was delivered using 60 Co or 6 MV X ray,with either a single beam or anterior-posterior beams.The total dose ranged from 20-60 Gy,with a median dose of 30 Gy. Results :Thoracic and lumbar vertebra,ribs and ilium were the most common metastatic sites.The median survival time was 34 months and 37.5 months in the entire cohort and in 112 cases with bone metastasis as first events respectively.Overall clinical response(complete and partial symptom relief) with radiation therapy was achieved in 90.8% of the patients with complete relief in 42.1% of all cases.The onset of symptom relief occurred within 4 weeks after the end of radiotherapy in 75.3% of the patients.The median duration of symptom relief was 23 month,which was over 22 months in those received a BED of ≥39 Gy,and 8 months in the sub-group of ≤30 Gy or less.Hormone receptors status,number of positive nodes,viscera metastasis,and solitary vs multiple skeletal metastases were independent prognostic factors for survival by multivariate analyses. Conclusions :Radiotherapy is an effective palliative approach for patients with bone metastases of breast cancer.Majority of the patients benefited from clinical response and the median duration of symptom relief lasted about 2/3 of the remaining survival time.Receptors status,number of positive nodes,viscera involvement,and solitary vs multiple skeletal metastases were independent prognostic factors for survival.

Clinical Effect of 89srcl2 in the Treatment of Breast Cancer Patients with Bone Metastasis

89Srcl2 in the Treatment of Cancer Patients with Bone Metastasis and Pain

THE EFFICACY OF 89 SRCL2 FOR BONE METASTASES IN MALIGNANT TUMOR

Preliminary Clinical Study of 89sr in Palliation in Painful Skeletal Metastases

A multicentre study on 89SrCl2 therapy in patients with painful bone metastases

Efects of Strontium-89 combined with Zoledronic acid for bone metastases

Comparison of the Efficacy of Strontium-89 Chloride in Treating Bone Metastasis of Lung, Breast, and Prostate Cancers

Clinical Study of 89 Sr Therapy with Radiosensitization by Nicotinamide and Carbogen in Multiple Bone Metastasis of Malignant Neoplasms

[Strontium-89: a Desirable Therapeutic for Bone Metastases of Prostate Cancer].

To evaluate the treating effect of strontium-89 (89Sr) on prostate cancer bone metastases by bone imaging

Combining Strontium-89 with ~(99)Tc-MDP for treatment of:painful bone metastases of prostate cancer

Comparison of palliating pain with 89SrCl2 and 153Sm-EDTMP in 57 lung cancer patients

Clinical analysis of bone metastasis treated by 125I radioactive seeds implantation

[Internal Strontium-89 Radiotherapy for Malignant Bony Metastasis].

Experimental Study on Roles of 99Mtc-Hl91 Imaging and Carbogen Breathing in 32P-Colloid Interstitial Treatment of Malignant Tumor

Effect of CT guided implantation of 125Ⅰ radioactive particles in superficial malignant tumors

Interstitial ~(125)I seed implantation in the treatment of metastatic and recurrent bone neoplasms

Radiotherapeutic Management and Prognostic Factors for Patients with Bone Metastases of Postoperative Breast Cancer

The Use of Radiopharmaceuticals for Metastatic Bone Pain in Cancer Patients

Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study.

Radionuclide therapy of patients with metastastic bone pain